Latest News

Keep up to date with all our latest investments, service offerings and news items.

Click here to view our latest media kit

  • September 26, 2019

    Almac’s unique gene expression report enables cancer researchers to discover exciting new insights

  • July 31, 2019

    Almac Diagnostic Services Launches Sample Management Service

  • July 31, 2019

    Almac Diagnostic Services receives CIR (French Research Tax Credit) Accreditation

  • June 5, 2019

    Almac Group Announces CE Mark of Diagnostic Assay to Support Turning Point Therapeutics’ Pivotal TRIDENT-1 Clinical Trial

  • May 6, 2019

    Turning Point Therapeutics and Almac Diagnostic Services announce approval of an investigational device exemption for the companion diagnostic assay to the registrational TRIDENT-1 clinical study

  • April 18, 2019

    Almac Group Partner with Queen’s Researchers to pioneer potentially life-changing oesophageal cancer test

  • March 27, 2019

    Almac Group Launches Upgraded Version of claraT – A Unique, Software-driven Gene Expression Report

  • October 24, 2018

    TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing, Pan-Cancer Companion Diagnostic

  • October 19, 2018

    Almac Group Launches claraT – A Unique, Software-driven Gene Expression Report

  • October 11, 2018

    Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients

  • October 10, 2018

    Almac Group Invests to Expand its Existing North Carolina Facility

  • April 16, 2018

    Almac Diagnostic Services Validates Illumina TruSight® Tumor 170 Cancer Mutation Panel for Prospective Testing in Clinical Trials

  • February 12, 2018

    Almac Diagnostic Services Partners with DNAnexus to Power Clinical Trial Assay Development

  • October 23, 2017

    Queen’s University Belfast in Collaboration with Almac Group Lead Largest Study of its Kind to Transform Prostate Cancer Treatment

  • June 13, 2017

    Almac Group Awarded U.S. Patents for Ground-breaking “DDRD” Assay

  • April 20, 2017

    Almac Group Announces Publication of Prostate Cancer Metastatic Assay Validation

  • March 8, 2017

    Almac Diagnostic Services and EORTC Establish Collaboration for Tumor Molecular Profiling

  • February 16, 2017

    Almac Diagnostic Services Appoints Dr Leeona Galligan as Vice President UK Operations

  • October 10, 2016

    Almac Group Discover an Exciting Link between its Immune Response Assay and Checkpoint Inhibitor Based Therapy

  • October 4, 2016

    Almac Diagnostic Services Partner with ArcherDX

  • August 8, 2016

    Almac Publish Second Validation of Stage II Colon Cancer Recurrence Assay in the Journal of Clinical Oncology

  • June 8, 2016

    Almac Diagnostic Services Expand Companion Diagnostic Development Service Offering with NanoString Barcoding Technology

  • March 8, 2016

    Almac Group Opens Additional Companion Diagnostic Laboratory in Durham NC USA

  • November 12, 2015

    Almac Group to Collaborate with Illumina on Next-Generation Sequencing Based Companion Diagnostic Development

  • July 10, 2015

    Almac Group Announce Companion Diagnostic Partnerships with OncoMed

  • March 3, 2015

    Almac Group Appoints Dr. Shirin Khambata Ford as VP Product Development

  • February 5, 2015

    Almac Appoints VP Quality and Regulatory Affairs

  • January 28, 2014

    Data Presented Supporting Almac Developed Colon Signature as a Significant Predictor of Risk of Recurrence in Stage II Colon Cancer

  • January 21, 2014

    Almac publishes breast cancer chemotherapy response assay in the Journal of the National Cancer Institute

  • November 26, 2013

    Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer

  • September 10, 2013

    Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service

  • February 1, 2012

    Almac announce launch of Next Generation Sequencing (NGS) Data Analysis Services

  • November 30, 2011

    Almac’s Diagnostic Laboratory Receives Accreditation from College of American Pathologists

  • November 8, 2011

    Almac publishes Stage II colon cancer recurrence signature in the Journal of Clinical Oncology

  • September 7, 2011

    Almac-Queen’s cancer expert to lead £4.4m collaboration

  • July 4, 2011

    Almac to perform the analytic phase of AclarusDx™ for Exonhit

  • May 31, 2011

    Almac data to be presented at annual ASCO meeting

  • March 30, 2011

    Almac open CLIA lab for biomarker clinical trials

  • March 1, 2011

    Live Webinar March 28th: An Integrated Approach to Biomarker Discovery

  • February 17, 2011

    Almac announce Launch of Bioinformatics Consultancy

  • August 26, 2010

    Almac Discusses New Biomarker Service on

  • August 2, 2010

    Almac launch Biomarkers for biopharma

  • June 28, 2010

    Almac Announces Collaboration with Aeterna Zentaris to Develop Therapy and Companion Diagnostic in Cancer

  • June 3, 2010

    Almac Launch Xcel Array – the Optimum Platform for Biomarker Discovery

  • April 12, 2010

    Almac partners with Merck KGaA and the MRC to assess markers of response to Cetuximab therapy

  • December 1, 2009

    Bioinformatics Expansion Heralds Further Growth for Almac

  • September 15, 2009

    Almac and Lilly Partner on Companion Diagnostic Development

  • July 28, 2009

    UM Breast Cancer Researchers partner with Almac to win prestigious Department of Defense Grant

  • July 9, 2009

    Official opening of Almac Diagnostic Services headquarters

  • April 29, 2009

    Dr Tanney Discusses Challenges Faced in Fine Tuning Sample Preparation Techniques

  • April 6, 2009

    Almac Group Uses HP Technology to Bring New Drugs to Market Faster

  • March 10, 2009

    Almac Collect Top Recognition for New Ovarian Cancer Research Product

  • January 8, 2009

    Almac Selects NuGEN Ovation® Systems to Broaden Gene Expression

  • November 27, 2008

    Almac addresses leading cancer specialists at All-Ireland conference

  • September 16, 2008

    Almac Diagnostic Services Launches Ovarian Cancer Research Tool

  • July 31, 2008

    Almac Announce World’s Largest Gene Expression Study To Develop Prognostic Test for Early Non Small Cell Lung Cancer

  • June 27, 2008

    Almac Diagnostic Services Join Personalized Medicine Coalition

  • May 8, 2008

    Almac Diagnostic Services in new deal to provide unique process to extract genetic information from Clinical Trial samples

  • February 26, 2008

    Almac Inks 15-Year Deal with Affy to Secure Rights to Develop and Sell Array-Based Dxs

  • February 21, 2008

    Almac Diagnostic Services Extends Agreement with Affymetrix

  • December 18, 2007

    Almac wins top award at Tech Idol Showcase

  • November 20, 2007

    BRCA1 Mutations Influence Cancer Cells’ Response to Drugs

  • August 8, 2007

    Almac Diagnostic Services Announces Pioneering Genetic Research on Ductal Carcinoma In Situ (DCIS) Using Breast Cancer DSA™ Research Tool

  • May 31, 2007

    Almac Diagnostic Services Attends Pre-ide Meeting With FDA for Colorectal Cancer Diagnostic Derived from FFPE Tissue Craigavon, Northern Ireland, 28 May 2007

  • April 16, 2007

    Almac Diagnostic Services Announces Pioneering Genetic Research

  • December 19, 2006

    Diagnostic Services Multi Year License Agreement With GeneGo

  • March 9, 2006

    Eirx Therapeutic Plc & Diagnostic Services Agreement

  • January 11, 2006

    Almac Diagnostic Services Receives ISO17025 Accreditation

  • January 10, 2006

    ArraDx Joins Almac Sciences – Now Almac Diagnostic Services

  • August 23, 2004

    Company Name Change